Trending NewsTrending NewsNYSE:JNJ Johnson & Johnson (JNJ) Stock Price, News & Analysis $168.29 -1.27 (-0.75%) Closing price 07/25/2025 03:59 PM EasternExtended Trading$168.38 +0.09 (+0.06%) As of 07/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Johnson & Johnson Stock (NYSE:JNJ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Johnson & Johnson alerts:Sign Up Key Stats Today's Range$167.44▼$169.8850-Day Range$149.81▼$169.6252-Week Range$140.68▼$169.99Volume6.20 million shsAverage Volume8.38 million shsMarket Capitalization$404.92 billionP/E Ratio18.00Dividend Yield3.09%Price Target$174.50Consensus RatingModerate Buy Company Overview Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. Read More Johnson & Johnson Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreJNJ MarketRank™: Johnson & Johnson scored higher than 97% of companies evaluated by MarketBeat, and ranked 41st out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingJohnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 9 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageJohnson & Johnson has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Johnson & Johnson's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.63% Earnings GrowthEarnings for Johnson & Johnson are expected to grow by 4.63% in the coming year, from $10.58 to $11.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Johnson & Johnson is 18.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Johnson & Johnson is 18.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.19.Price to Earnings Growth RatioJohnson & Johnson has a PEG Ratio of 2.16. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJohnson & Johnson has a P/B Ratio of 5.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.66% of the float of Johnson & Johnson has been sold short.Short Interest Ratio / Days to CoverJohnson & Johnson has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Johnson & Johnson has recently decreased by 3.12%, indicating that investor sentiment is improving. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldJohnson & Johnson pays a meaningful dividend of 3.07%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthJohnson & Johnson has been increasing its dividend for 64 years.Dividend CoverageThe dividend payout ratio of Johnson & Johnson is 55.61%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 46.97% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.Read more about Johnson & Johnson's dividend. Sustainability and ESG3.9 / 5Environmental Score-1.98 Percentage of Shares Shorted0.66% of the float of Johnson & Johnson has been sold short.Short Interest Ratio / Days to CoverJohnson & Johnson has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Johnson & Johnson has recently decreased by 3.12%, indicating that investor sentiment is improving. News and Social Media4.0 / 5News Sentiment1.28 News SentimentJohnson & Johnson has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 121 news articles for Johnson & Johnson this week, compared to 76 articles on an average week.Search Interest119 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 37% compared to the previous 30 days.MarketBeat Follows43 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Johnson & Johnson insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.16% of the stock of Johnson & Johnson is held by insiders.Percentage Held by Institutions69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Johnson & Johnson's insider trading history. Receive JNJ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter. Email Address JNJ Stock News HeadlinesJNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is NowJohnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.July 24 at 5:50 PM | marketbeat.com4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise (JNJ)With solid Q2 results and 2025 guidance increases, Wall Street is upgrading these four stocks. Analysts now see palpable upside in one streaming stalwart.July 23 at 7:13 AM | marketbeat.comCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. | Timothy Sykes (Ad)Build Stability and Income With 3 Overlooked Dividend Leaders (JNJ)Three dividend-paying stocks with high yields present an opportunity for significant passive income but a potentially high dividend payout ratio.July 21, 2025 | marketbeat.comWant Steady Income? 3 Top Dividend Stocks for July 2025 (JNJ)Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility...July 17, 2025 | marketbeat.comJohnson & Johnson Submits NDA for Protagonist-Partnered Icotrokinra to FDA for Plaque PsoriasisJuly 25 at 5:50 PM | msn.comUS FDA says J&J's Ethicon issues correction related to surgical staplerJuly 25 at 11:48 AM | reuters.comJohnson & Johnson (JNJ) Partnership Bolsters Pacira's Growth | JNJ Stock NewsJuly 25 at 6:42 AM | gurufocus.comSee More Headlines JNJ Stock Analysis - Frequently Asked Questions How have JNJ shares performed this year? Johnson & Johnson's stock was trading at $144.62 at the start of the year. Since then, JNJ stock has increased by 16.4% and is now trading at $168.2920. How were Johnson & Johnson's earnings last quarter? Johnson & Johnson (NYSE:JNJ) issued its earnings results on Wednesday, July, 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The business's revenue was up 5.8% compared to the same quarter last year. Read the conference call transcript. Does Johnson & Johnson have any subsidiaries? Johnson & Johnson subsidiaries include these companies: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and others. Who are Johnson & Johnson's major shareholders? Johnson & Johnson's top institutional shareholders include Ninety One UK Ltd (0.29%), Assenagon Asset Management S.A. (0.17%), Aberdeen Group plc (0.11%) and Kingstone Capital Partners Texas LLC (0.10%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Peter Fasolo, William Hait, Kathryn E Wengel, Ashley Mcevoy, Thibaut Mongon, Joseph J Wolk, Robert J Decker, Timothy Schmid, James D Swanson and Mark A Weinberger. View institutional ownership trends. How do I buy shares of Johnson & Johnson? Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Johnson & Johnson own? Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), UnitedHealth Group (UNH), Gilead Sciences (GILD), Corning (GLW), NextEra Energy (NEE) and Devon Energy (DVN). Company Calendar Record date for 6/10 Dividend5/27/2025Ex-Dividend for 6/10 Dividend5/27/2025Dividend Payable6/10/2025Last Earnings7/16/2025Today7/26/2025Record date for 9/9 Dividend8/26/2025Ex-Dividend for 9/9 Dividend8/26/2025Dividend Payable9/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Large Cap Pharma Sub-IndustryPharmaceuticals Current SymbolNYSE:JNJ CIK200406 Webwww.jnj.com Phone(732) 524-0400Fax732-214-0332Employees138,100Year Founded1886Price Target and Rating Average Price Target for Johnson & Johnson$174.50 High Price Target$215.00 Low Price Target$152.00 Potential Upside/Downside+3.7%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage20 Analysts Profitability EPS (Trailing Twelve Months)$9.35 Trailing P/E Ratio18.00 Forward P/E Ratio15.91 P/E Growth2.16Net Income$14.07 billion Net Margins25.00% Pretax Margin30.17% Return on Equity33.07% Return on Assets13.16% Debt Debt-to-Equity Ratio0.49 Current Ratio1.26 Quick Ratio1.03 Sales & Book Value Annual Sales$88.82 billion Price / Sales4.56 Cash Flow$13.03 per share Price / Cash Flow12.92 Book Value$29.69 per share Price / Book5.67Miscellaneous Outstanding Shares2,406,070,000Free Float2,402,223,000Market Cap$404.92 billion OptionableOptionable Beta0.41 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NYSE:JNJ) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Johnson & Johnson Please log in to your account or sign up in order to add this asset to your watchlist. Share Johnson & Johnson With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.